次要发现(SF)的检测和披露是医学上可操作的遗传性健康状况的预防策略。一些国家有关于SFs的管理和披露的指导方针,而其他人则避免检测和披露SFs。这项研究是对六个国家和欧盟的临床指南的回顾,以确定SF指南之间的异同。本审查的证据支持各国协调指南,以促进基因组学方面的广泛国际合作,并使精准医学受益。本研究可为中国SF管理指南的制定提供参考,为其他国家在伦理和方法上的挑战提供证据。
The detection and disclosure of secondary findings (SFs) is a preventive strategy for medically-actionable hereditary health conditions. Some countries have
guidelines on management and disclosure of SFs, while others avoid detection and disclosure of SFs. This study is a review of clinical
guidelines from six countries and the European Union to identify similarities and differences among SF
guidelines. Evidence from this review supports harmonization of
guidelines across countries to promote broad international collaborations on genomics and to benefit precision medicine. This study can serve as a reference for development of SF management
guidelines in China by contributing evidence from other countries to the ethical and methodological challenges under debate.